Canine Natural Killer Cell‐Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor
Jienny Lee, Se-A Lee, Na‐Yeon Gu, So Yeon Jeong, Jeong Su Byeon, Da-Un Jeong, In-Ohk Ouh, Yoon-Hee Lee, Bang‐Hun Hyun
Abstract
Natural killer (NK) cells are key immune cells engaged in fighting infection and malignant transformation. In this study, we found that canine NK cell‐derived exosomes (NK‐exosomes) separated from activated cytotoxic NK cell supernatants express specific markers including CD63, CD81, Alix, HSP70, TSG101, Perforin 1, and Granzyme B. We examined the antitumor effects of NK‐exosomes in an experimental murine mammary tumor model using REM134 canine mammary carcinoma cell line. We observed changes in tumor size, tumor initiation, progression, and recurrence‐related markers in the control, tumor group, and NK‐exosome‐treated tumor group. We found that the tumor size in the NK‐exosome‐treated tumor group decreased compared with that of the tumor group in the REM134‐driven tumorigenic mouse model. We observed significant changes including the expression of tumorigenesis‐related markers, such as B cell‐specific Moloney murine leukemia virus insertion site 1 (Bmi‐1), vascular endothelial growth factor (VEGF), matrix metallopeptidase‐3 (MMP‐3), interleukin‐1 β (IL‐1 β ), IL‐6, tumor necrosis factor‐ α (TNF‐ α ), multidrug resistance protein (MDR), tumor suppressor protein p53 (p53), proliferating cell nuclear antigen (PCNA), and the apoptotic markers, B cell lymphoma‐2 associated X (Bax) and B cell lymphoma‐extra large (Bcl‐xL) belonging to the Bcl‐2 family, in the tumor group compared with those in the control group. The expression of CD133, a potent cancer stem cell marker, was significantly higher than that of the control. By contrast, the NK‐exosome‐treated tumor group exhibited a significant reduction in Bmi‐1, MMP‐3, IL‐1 β , IL‐6, TNF‐ α , Bax, Bcl‐xL, and PCNA expression compared with that in the tumor group. Furthermore, the expression of CD133, which mediates tumorigenesis, was significantly decreased in the NK‐exosome‐treated tumor group compared with that in the tumor group. These findings indicate that canine NK‐exosomes represent a promising therapeutic tool against canine solid tumors, including mammary carcinoma.